128 related articles for article (PubMed ID: 25969169)
1. A solid-phase combinatorial approach for indoloquinolizidine-peptides with high affinity at D(1) and D(2) dopamine receptors.
Molero A; Vendrell M; Bonaventura J; Zachmann J; López L; Pardo L; Lluis C; Cortés A; Albericio F; Casadó V; Royo M
Eur J Med Chem; 2015 Jun; 97():173-80. PubMed ID: 25969169
[TBL] [Abstract][Full Text] [Related]
2. Indoloquinolizidine-peptide hybrids as multiple agonists for D1 and D2 dopamine receptors.
Vendrell M; Soriano A; Casadó V; Díaz JL; Lavilla R; Canela EI; Lluís C; Franco R; Albericio F; Royo M
ChemMedChem; 2009 Sep; 4(9):1514-22. PubMed ID: 19557804
[TBL] [Abstract][Full Text] [Related]
3. A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors.
Soriano A; Vendrell M; Gonzalez S; Mallol J; Albericio F; Royo M; Lluís C; Canela EI; Franco R; Cortés A; Casadó V
J Pharmacol Exp Ther; 2010 Mar; 332(3):876-85. PubMed ID: 20026675
[TBL] [Abstract][Full Text] [Related]
4. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
5. Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists.
Pereira NA; Sureda FX; Pérez M; Amat M; Santos MM
Molecules; 2016 Aug; 21(8):. PubMed ID: 27509489
[TBL] [Abstract][Full Text] [Related]
6. Structure-Guided Screening for Functionally Selective D
Männel B; Jaiteh M; Zeifman A; Randakova A; Möller D; Hübner H; Gmeiner P; Carlsson J
ACS Chem Biol; 2017 Oct; 12(10):2652-2661. PubMed ID: 28846380
[TBL] [Abstract][Full Text] [Related]
7. Ligand-optimized homology models of D₁ and D₂ dopamine receptors: application for virtual screening.
Kołaczkowski M; Bucki A; Feder M; Pawłowski M
J Chem Inf Model; 2013 Mar; 53(3):638-48. PubMed ID: 23398329
[TBL] [Abstract][Full Text] [Related]
8. 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms.
Grubbs RA; Lewis MM; Owens-Vance C; Gay EA; Jassen AK; Mailman RB; Nichols DE
Bioorg Med Chem; 2004 Mar; 12(6):1403-12. PubMed ID: 15018913
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
Szabo M; Klein Herenbrink C; Christopoulos A; Lane JR; Capuano B
J Med Chem; 2014 Jun; 57(11):4924-39. PubMed ID: 24827597
[TBL] [Abstract][Full Text] [Related]
10. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
Zou MF; Keck TM; Kumar V; Donthamsetti P; Michino M; Burzynski C; Schweppe C; Bonifazi A; Free RB; Sibley DR; Janowsky A; Shi L; Javitch JA; Newman AH
J Med Chem; 2016 Apr; 59(7):2973-88. PubMed ID: 27035329
[TBL] [Abstract][Full Text] [Related]
11. Biotin ergopeptide probes for dopamine receptors.
Vendrell M; Molero A; González S; Pérez-Capote K; Lluis C; McCormick PJ; Franco R; Cortés A; Casadó V; Albericio F; Royo M
J Med Chem; 2011 Feb; 54(4):1080-90. PubMed ID: 21280602
[TBL] [Abstract][Full Text] [Related]
12. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
[TBL] [Abstract][Full Text] [Related]
13. 2,3,9- and 2,3,11-trisubstituted tetrahydroprotoberberines as D2 dopaminergic ligands.
Párraga J; Cabedo N; Andujar S; Piqueras L; Moreno L; Galán A; Angelina E; Enriz RD; Ivorra MD; Sanz MJ; Cortes D
Eur J Med Chem; 2013 Oct; 68():150-66. PubMed ID: 23974015
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and binding affinity of new 1,4-disubstituted triazoles as potential dopamine D(3) receptor ligands.
Insua I; Alvarado M; Masaguer CF; Iglesias A; Brea J; Loza MI; Carro L
Bioorg Med Chem Lett; 2013 Oct; 23(20):5586-91. PubMed ID: 24012118
[TBL] [Abstract][Full Text] [Related]
15. N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists.
Herm L; Berényi S; Vonk A; Rinken A; Sipos A
Bioorg Med Chem; 2009 Jul; 17(13):4756-62. PubMed ID: 19454369
[TBL] [Abstract][Full Text] [Related]
16. Molecular insights into the D1R agonist and D2R/D3R antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.
Li B; Li W; Du P; Yu KQ; Fu W
J Phys Chem B; 2012 Jul; 116(28):8121-30. PubMed ID: 22702398
[TBL] [Abstract][Full Text] [Related]
17. Dynamic combinatorial chemistry as a rapid method for discovering sequence-selective RNA-binding compounds.
McAnany JD; Miller BL
Methods Enzymol; 2019; 623():67-84. PubMed ID: 31239058
[TBL] [Abstract][Full Text] [Related]
18. Screening and isolation of a natural dopamine D1 receptor antagonist using cell-based assays.
Yu S; Park JS; Paredes V; Song MC; Baek NI; Lee SI; Lim JS; Cho NY; Yoon J; Baek K
J Biotechnol; 2010 Feb; 145(3):304-9. PubMed ID: 19963021
[TBL] [Abstract][Full Text] [Related]
19. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
20. Click chemistry based solid phase supported synthesis of dopaminergic phenylacetylenes.
Rodriguez Loaiza P; Löber S; Hübner H; Gmeiner P
Bioorg Med Chem; 2007 Dec; 15(23):7248-57. PubMed ID: 17827018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
